Industrialization condition and development strategy of Paridis Rhizoma
10.7501/j.issn.0253-2670.2020.18.026
- VernacularTitle: 重楼产业现状及发展对策
- Author:
Ai-En TAO
1
Author Information
1. College of Lijiang of Tourism and Culture, Yunnan University
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Development countermeasures;
Industry status;
Paridis Rhizoma;
Resource ecology
- From:
Chinese Traditional and Herbal Drugs
2020;51(18):4809-4815
- CountryChina
- Language:Chinese
-
Abstract:
As an important Chinese medicinal material in China, Paridis Rhizoma has obvious curative effect and has analgesic, hemostasis, anti-inflammatory and anti-tumor activities. At present, it is the main raw material of 262 kinds of Chinese patent medicines such as Yunnan Baiyao and Gongxuening Capsule, and has important economic and social value in the Chinese medicine industry. The author mainly systematically summarizes the medicinal history and origin changes of Paridis Rhizoma, the history of industrial development, the status quo of ethnic and folk applications, the status quo of development and application of proprietary Chinese medicines, and the study of resource ecology and breeding, and proposes the implementation of the process of industrialization of Paridis Rhizoma. Important issues and countermeasures need to be paid attention in order to provide reference for the sound development of Paridis Rhizoma.
